Press Releases

  Muscular Dystrophy Canada and partners deliver on goal outlined in Canada’s Rare Disease Strategy Toronto, Ontario, Canada, August 20, 2024 – Muscular Dystrophy Canada is thrilled to announce that after three years of working with each Canadian province and territory, all babies born in Canada can now be tested for spinal muscular atrophy (SMA). This …Continue Reading

Muscular Dystrophy Canada (MDC) is pleased to announce the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects focused on managing healthcare, understanding diagnosis and disease progression, enhancing care, discovering novel treatments and therapies and moving research towards the development of cures. This …Continue Reading

FOR IMMEDIATE RELEASE – Muscular Dystrophy Canada (MDC) together with the Neuromuscular Disease Network for Canada (NMD4C) are thrilled to announce the recipients of the National Clinical and Post-doctoral Fellowships funding competition. This competition involves an extensive review by leading Canadian neuromuscular researchers and clinicians to ensure the top-ranked candidates are selected for this funding opportunity. “Too …Continue Reading

Muscular Dystrophy Canada does not use telemarketing services. You can support Fire Fighters and help them Fill the Boot for Muscular Dystrophy Canada and the individuals and families affected by neuromuscular disorders by going to filltheboot.ca. STATEMENT REGARDING PHONE SOLICITATIONS Several years ago, the Canadian Fire Fighter Curling Association (CFFCA) retained a telemarketing company to …Continue Reading

Toronto, Ontario – Access to innovative care is vital for Canadians living with myasthenia gravis (MG) to help relieve the considerable impact faced by those affected by this rare neuromuscular disorder. For the first time in over 30 years, treatment advancements for adults with refractory MG have been approved in Canada, bringing hope to those for …Continue Reading

We want to bring your attention to recent developments surrounding the availability of Deflazacort®/Calcort®, a corticosteroid vital to many Canadians affected by Duchenne muscular dystrophy. Up until 2023, Deflazacort was accessible at a relatively low cost in Canada through Health Canada’s Special Access Program despite intermittent supply shortages. In February, due to a change in …Continue Reading

FOR IMMEDIATE RELEASE – Muscular Dystrophy Canada (MDC) is thrilled to announce that spinal muscular atrophy (SMA) has been added to the newborn screening panel in Quebec. A significant milestone for the province and MDC. “Congratulations to the Government of Quebec on this step, which will lead to early diagnosis and treatments that will have …Continue Reading

Neuromuscular Disease Network for Canada Awarded 5-Year Grant from CIHR-IMHA and Funding from MDC to Strengthen Canadian Neuromuscular Research and Care For Immediate Release: June 21, 2023 Toronto, ON – The Neuromuscular Disease Network for Canada (NMD4C) has received a network grant from the Canadian Institutes of Health Research – Institute of Musculoskeletal Health and …Continue Reading

FOR IMMEDIATE RELEASE June 16, 2023 Toronto, Ontario – The 2023 Walk and Roll for Muscular Dystrophy Canada (MDC) has changed venues from a local park to the Abilities Centre in Whitby in an effort to ensure the event is as accessible as possible for all participants. It takes place on June 25, 2023. “MDC …Continue Reading

For immediate release Montréal, April 28, 2023 – It is with great enthusiasm that Génome Québec, Ataxia Canada and Muscular Dystrophy Canada announce the launch of the Innovative Therapies for Hereditary Ataxias competition to encourage the discovery and development of new therapies and to mobilize the research ecosystem. The three organizations aim to jointly invest $1M …Continue Reading